Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

Leukemia
G J RobozEric J Feldman

Abstract

PTK787/ZK 222584 (PTK/ZK) is an oral angiogenesis inhibitor targeting vascular endothelial growth factor (VEGF) receptor tyrosine kinases, including VEGFR-1/Flt-1, VEGFR-2/KDR, VEGFR-3/Flt-4, the platelet-derived growth factor receptor tyrosine kinase and the c-kit protein tyrosine kinase. The objective of this Phase I study was to evaluate the safety, tolerability, biologic activity and pharmacologic profile of PTK/ZK administered orally, twice daily, on a continuous dosing schedule in patients with primary refractory or relapsed acute myeloid leukemia (AML), secondary AML, poor-prognosis de novo AML or advanced myelodysplastic syndrome (MDS). Acute myeloid leukemia patients for whom PTK/ZK monotherapy was ineffective could receive PTK/ZK combined with standard induction chemotherapy. Sixty-three patients received PTK/ZK at doses of 500-1000 mg orally b.i.d. Safety and pharmacokinetic data were collected. Responses were evaluated according to standard bone marrow and peripheral blood criteria. At 1000 mg b.i.d., dose-limiting toxicities of lethargy, hypertension, nausea, emesis and anorexia were observed. Other adverse events related to PTK/ZK were dizziness, weakness, fatigue, diarrhea and pruritus; these were generally mild ...Continue Reading

References

Apr 1, 1994·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·D Weinstat-Saslow, P S Steeg
Jan 1, 1995·Breast Cancer Research and Treatment·N Ferrara
Dec 22, 1999·British Journal of Cancer·G PruneriF Pezzella
Aug 23, 2000·The Journal of Clinical Investigation·S DiasS Rafii
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·S DiasS Rafii
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Judith E KarpJames Zwiebel
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giampietro GaspariniBeverly A Teicher
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne L ThomasWilliam P Steward

❮ Previous
Next ❯

Citations

Jul 7, 2011·The Journal of Membrane Biology·Kim R Kampen
Jun 3, 2008·Annals of Hematology·Florian Nolte, Wolf-K Hofmann
Mar 21, 2007·Cancer Chemotherapy and Pharmacology·R Longo, G Gasparini
Dec 22, 2007·Current Treatment Options in Oncology·Alexander E Perl, Martin Carroll
Oct 22, 2008·Current Oncology Reports·Margaret E MacyLia Gore
Jan 10, 2012·Journal of Medicinal Chemistry·David K HeidaryGreg Henkel
May 1, 2007·DNA and Cell Biology·Shani ShiloChandan K Sen
Jan 31, 2008·Journal of the National Cancer Institute·Weiguo ZhangMichael Andreeff
May 29, 2010·Journal of Oncology·Michael MedingerAlexandar Tzankov
Sep 10, 2011·Journal of Oncology·Angelica TrujilloChristopher R Cogle
Jul 3, 2009·Journal of Vascular Research·Chandan K SenSashwati Roy
Aug 1, 2009·Journal of Hematology & Oncology·Jianbiao ZhouChien-Shing Chen
Jun 24, 2010·Journal of Angiogenesis Research·Michael Medinger, Klaus Mross
Jan 1, 2010·Cancer Management and Research·Christopher Rice, L Eric Huang
Jul 27, 2012·Cellular and Molecular Life Sciences : CMLS·Kim R KampenEveline S J M de Bont
Feb 17, 2007·Expert Opinion on Investigational Drugs·Edwina N ScottAnne L Thomas
Jul 16, 2015·Contrast Media & Molecular Imaging·Mohammed P I BhuiyanMeser M Ali
Nov 3, 2010·Critical Reviews in Oncology/hematology·Antonio Rodriguez-ArizaNuria Barbarroja
Jun 24, 2010·Critical Reviews in Oncology/hematology·Suzita M NoorAlister C Ward
Jan 23, 2009·Leukemia Research·Domenico Ribatti
Oct 28, 2008·Cancer Treatment Reviews·Andrea Kuendgen, Ulrich Germing
Aug 7, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Pedro M LacalStefania D'Atri
Mar 18, 2008·Best Practice & Research. Clinical Haematology·William Blum, Guido Marcucci
Jan 9, 2008·Seminars in Hematology·Magda Melchert, Alan List
Jul 31, 2007·Critical Reviews in Oncology/hematology·Kathrin T DoepfnerAlexandre Arcaro
Feb 20, 2007·Critical Reviews in Oncology/hematology·Sophie Sun, Joan H Schiller
Nov 28, 2008·British Journal of Haematology·William W LiGerald Gehr
Aug 30, 2012·European Journal of Haematology·Julian PaeslerKarl-Anton Kreuzer
May 13, 2015·Cancer Letters·Christopher R CogleNajmaldin Saki
May 12, 2005·Blood Reviews·Daniel V T Catenacci, Gary J Schiller
Oct 21, 2004·Best Practice & Research. Clinical Haematology·Elihu H Estey
Nov 22, 2014·Experimental & Molecular Medicine·Ji Yoon Lee, Hee-Je Kim
Sep 29, 2009·Cancer Chemotherapy and Pharmacology·Robin E Norris, Peter C Adamson

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anorexia Nervosa

Anorexia nervosa (AN) is a psychiatric condition characterized by severe weight loss and secondary problems associated with malnutrition. Here is the latest research on AN.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.